Looking ahead to 2025, Globus Medical has provided guidance that reflects both its standalone operations and the impact of its recent acquisition of Nevro Corp (NYSE:NVRO). The company expects net ...

TORONTO, May 15, 2025 (GLOBE NEWSWIRE) — EnviroGold Global Limited (CSE: NVRO | OTCQB: ESGLF | FSE: YGK) (“EnviroGold,” or the “Company”), a clean ...

TORONTO, May 15, 2025 (GLOBE NEWSWIRE) -- EnviroGold Global Limited (CSE: NVRO | OTCQB: ESGLF | FSE: YGK) (“EnviroGold,” or the “Company”), a ...

Process Optimisation, Strategic Alliances and Engineering Readiness Position Company for Market Entry EnviroGold’s proprietary NVRO Process™ is progressing toward commercialisation, following ...

Fintel reports that on May 27, 2025, BTIG downgraded their outlook for Globus Medical (BMV:GMED) from Buy to Neutral. There are 759 funds or institutions reporting positions in Globus Medical.

Globus Medical, Inc. GMED reported first-quarter 2025 adjusted earnings per share (EPS) of 68 cents, which missed the Zacks Consensus Estimate by 8.1%. The figure increased 7.9% year over year.